Ken Griffin
GTBP icon

Ken Griffin’s GT Biopharma GTBP Stock Holding History

Ken Griffin’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27K Sell
66,165
-14,596
-18% -$7.96K ﹤0.01% 12604
2025
Q4 		$63.4K Buy
80,761
+41,128
+104% +$29.2K ﹤0.01% 11918
2025
Q3 		$23.6K Buy
+39,633
New +$59.2K ﹤0.01% 12461
2025
Q2 		– Sell
-20,138
Closed -$45.1K – 13503
2025
Q1 		$45.1K Buy
+20,138
New +$47.4K ﹤0.01% 12412
2024
Q1 		– Sell
-1,927
Closed -$14.7K – 14910
2023
Q4 		$14.7K Buy
+1,927
New +$14.1K ﹤0.01% 12864
2023
Q2 		– Sell
-1,239
Closed -$20.4K – 14689
2023
Q1 		$20.4K Buy
+1,239
New +$28.4K ﹤0.01% 13052
2022
Q3 		– Sell
-2,033
Closed -$182K – 13002
2022
Q2 		$182K Buy
2,033
+466
+30% +$35.3K ﹤0.01% 10804
2022
Q1 		$135K Buy
1,567
+1,186
+311% +$105K ﹤0.01% 11967
2021
Q4 		$35K Sell
381
-90
-19% -$13.5K ﹤0.01% 13414
2021
Q3 		$95K Sell
471
-16,531
-97% -$4.98M ﹤0.01% 12938
2021
Q2 		$7.91M Buy
+17,002
New +$7.06M ﹤0.01% 3518

Other funds holding GTBP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
I
INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Ken Griffin's GTBP Position: Q1 2026 in Review

Ken Griffin reduced its GT Biopharma (GTBP) stake by 18% in Q1 2026, selling an estimated $7.96K and leaving 66,165 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #12604.

Ken Griffin first reported a position in GTBP in Q2 2021 and has held it in 11 quarters since. The position peaked at $7.91M in Q2 2021. 42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • Ken Griffin held 66,165 shares of GT Biopharma worth $27K as of Q1 2026.
  • Ken Griffin sold 14,596 GT Biopharma shares in Q1 2026, an estimated $7.96K.
  • GT Biopharma made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #12604 holding.
  • Ken Griffin first reported a position in GT Biopharma in Q2 2021 and has held it in 11 quarters since.
  • Ken Griffin's GT Biopharma position peaked at $7.91M in Q2 2021.
  • 42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.